دورية أكاديمية
Evaluation of Cannabis-Related Product Use Among Patients With Hidradenitis Suppurativa: A Narrative Review.
| العنوان: | Evaluation of Cannabis-Related Product Use Among Patients With Hidradenitis Suppurativa: A Narrative Review. |
|---|---|
| المؤلفون: | Shojaei D; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Zabihi H; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada., Maida V; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.; Division of Palliative Care, University of Toronto, Toronto, ON, Canada., Kirchhof MG; Department of Dermatology, Faculty of Medicine, University of Ottawa and the Ottawa Hospital, Ottawa, ON, Canada., Alavi A; Department of Dermatology, Mayo Clinic, Rochester, MN, USA. |
| المصدر: | Journal of cutaneous medicine and surgery [J Cutan Med Surg] 2024 Jul 31, pp. 12034754241266125. Date of Electronic Publication: 2024 Jul 31. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sage Publications Country of Publication: United States NLM ID: 9614685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1615-7109 (Electronic) Linking ISSN: 12034754 NLM ISO Abbreviation: J Cutan Med Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Thousand Oaks, CA : Sage Publications Original Publication: Hamilton, ON : BC Decker |
| مستخلص: | The use of cannabis and cannabis-related products among patients with hidradenitis suppurativa (HS) is increasing globally. Given the potential anti-inflammatory, therapeutic, and pain management benefits of cannabis-related products, we reviewed primary literature to evaluate the prevalence and possible purpose for cannabis use among patients with HS and to provide recommendations to patients and physicians. A narrative review of original studies was conducted using Embase and Ovid Medline databases. The search strategy was confirmed by a librarian and conducted on September 1, 2023, using a detailed list of subject headings and keywords tailored to cannabis, cannabis-related products, HS, and both adult and pediatric populations. Among 43 identified studies, 6 met the eligibility criteria and encompassed 34,435 patients. Patients were mostly female, and studies were conducted across the United States, Canada, and France. Findings show higher cannabis use among HS patients, demonstrating efficacy in pain management, sleep, anxiety relief, itch relief, and improved quality of life. Cannabis may play a role in analgesia, improved quality of life, pain, itch, and overall mental health in patients with HS and healthcare providers including dermatologists should increase their familiarity in appropriate use of cannabis-related products. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Alavi is a consultant for Abbvie, Admirall, BI, InflaRx, Incyte, Kymera, Novartis, UCB. She is a board member of Hidradenitis Suppurativa foundation and principal investigator for Processa and BI. Dr Maida is Chief Medical Scientist for Kensana Health Inc, which holds intellectual property and patents pertaining to cannabis-based medicines for integumentary and wound management. The rest of authors have no conflict of interest. |
| فهرسة مساهمة: | Keywords: clinical research; medical dermatology; patient care; substance use; treatment response |
| تواريخ الأحداث: | Date Created: 20240731 Latest Revision: 20240731 |
| رمز التحديث: | 20240731 |
| DOI: | 10.1177/12034754241266125 |
| PMID: | 39082368 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1615-7109 |
|---|---|
| DOI: | 10.1177/12034754241266125 |